FiercePharma17h
ASH: Incyte's Monjuvi triumphs in follicular lymphoma phase 3, teeing up FDA filing
Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...
FiercePharma19h
India’s Lupin recalls more than 600K bottles of blood pressure med over questionable API source
Indian drugmaker Lupin is recalling more than 600,000 bottles of the high blood pressure and heart failure drug ramipril due ...
FiercePharma19h
Bristol Myers Squibb hands pink slips to 195 workers in New Jersey as cost-cutting effort rolls on
Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. | Bristol Myers Squibb has ...
FiercePharma21h
A possible ban on DTC pharma ads poses 'biggest threat' of RFK Jr.'s HHS appointment: analyst
With Robert F. Kennedy Jr. slated to take the top spot at the U.S. | RFK Jr. has previously expressed a desire to put a stop ...
FiercePharma23h
Merck preps filings after blockbuster-in-waiting Winrevair succeeds in severe PAH study
Eight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 ...